Nesiritide citrate (Scios).
Nesiritide citrate is a human brain natriuretic peptide under development by Scios for the potential treatment of congestive heart failure (CHF). An NDA was submitted to the US FDA in April 1998 for approval to market nesiritide citrate for short-term CHF. Scios is expecting to launch this product by mid-1999. Animal studies at Scios have also indicated that human brain natriuretic peptide may be useful in the management of acute hypertension associated with numerous surgical procedures. Scios has estimated the potential market for this drug to be 250-300 million dollars in the US alone.
Light
P
P
Department of Physiology and Biophysics, University of Calgary, Alberta, Canada. plight@acs.ucalgary.ca